On Friday, Cantor Fitzgerald initiated protection on Summit Therapeutics Inc. SMMT, citing shares as 67% undervalued.
The corporate’s lead candidate ivonescimab (SMT112) is an investigational, doubtlessly first-in-class bispecific antibody combining the results of immunotherapy through a blockade of PD-1 with the anti-angiogenesis results related to blocking VEGF right into a single molecule.
Akeso Inc. engineered Ivonescimab, which is at present in a number of Part 3 medical trials. Over 2,300 sufferers have been handled with ivonescimab in medical research globally.
Additionally Learn: Summit Therapeutics ‘Distinctive Funding In Oncology,’ Lead Drug Candidate Exhibits Promise Over Keytruda And Opdivo
Analyst Eric Schmidt writes, “Merely put, ought to ivonescimab proceed to ship superior efficacy relative to a PD-(L)1 class ($50 billion and rising in 2024 gross sales), it may develop into one of the vital profitable medication ever.”
Cantor analyst has initiated Summit Therapeutics with an Obese ranking.
Cantor writes that ivonescimab is efficient and protected, standing out from single-antibody mixtures as a result of its distinctive cooperative binding mechanism. Whereas different VEGF x PD-(L)1 bispecific medication would possibly share some similarities, ivonescimab has a major head begin and will launch within the U.S. by late 2026.
In September, Summit Therapeutics launched knowledge from the first evaluation of the Part 3 HARMONi-2 trial of ivonescimab performed in China.
Ivonescimab monotherapy demonstrated a statistically vital enchancment within the trial’s main endpoint, progression-free survival, in comparison with monotherapy Merck & Co Inc’s MRK Keytruda (pembrolizumab), attaining a hazard ratio (HR) of 0.51.
Cantor writes that progression-free survival is more likely to translate into improved general survival, with knowledge anticipated by the top of 2025 or early 2026.
“Rising conviction in HARMONi-2 ought to improve investor optimism for Summit’s three ongoing Part 3 trials in NSCLC with readouts anticipated in 2025-2028,” analyst Schmidt writes.
Cantor notes that ivonescimab may obtain round 50% share within the over $100 billion marketplace for VEGF x PD-(L)1s.
Worth Motion: Summit Therapeutics inventory is up 3.44% at $20.43 on the final test Monday.
Learn Subsequent:
Momentum99.03
Progress–
High quality–
Worth–
Market Information and Information dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
